AstraZeneca to buy Alexion for $39 billion
Britain’s AstraZeneca has agreed to buy US drug maker Alexion Pharmaceuticals for $39 billion in cash and shares to bolster its positions in immunology and rare diseases. AstraZeneca, one of the frontrunners in the drug industry’s search for a COVID-19 vaccine, said on Saturday that Alexion shareholders would receive $60 in cash and about $1...